Oxford Drug Design is pleased to announce the appointment of Dr. Pamela Brown FRSC to the company’s Scientific Advisory Board. Dr. Brown has over 30 years’ experience in anti-infective drug discovery. Pam has previously led medicinal chemistry teams in hit to lead and lead optimisation phases of drug discovery at GlaxoSmithKline and legacy companies. In 2008, Pam joined BioFocus, where she co-led integrated drug discovery projects towards a variety of targets. Pam joined Cantab Anti-infectives as director of medicinal chemistry in 2012, leading the medicinal chemistry team towards novel polymyxins, resulting in a commercial deal with Spero Therapeutics in 2016 and the selection of a preclinical candidate in 2017. Since 2017, Pam has operated as an independent consultant in antibacterial drug discovery and medicinal chemistry with clients in the UK, Europe and the US.